We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Viropro and Invitrogen Signs R&D Collaboration Agreement

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Viropro Inc. and Invitrogen Corp. have entered into an R&D collaboration in which Invitrogen is testing and helping to develop production technologies.

Viropro's protein production expertise combined with Invitrogen PD Direct™'s media and cell line development expertise will yield new solutions for pharmaceutical and biotech companies.

This collaboration would represent recurring revenues and royalties for Viropro following integration of the technology with Invitrogen PD Direct™'s customized media platforms.

Additionally, Viropro has an opportunity to out-license the technology and sign intellectual property (IP) agreements with other major biotech companies interested in integrating novel IP into their research and manufacturing processes.

“The fact that an industry leader like Invitrogen has shown a concrete interest in our technology is a clear sign of Viropro's ability to choose innovative and cutting edge intellectual property for the realization of our business model,” said Viropro CEO, Jean-Marie Dupuy.

Jeff Greenberg, VP of BioProduction of Invitrogen stated that, “We are enthusiastic about testing this new technology and hope to establish a long-term relationship with Viropro.”